NASDAQ:PRE Prenetics Global (PRE) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free PRE Stock Alerts $3.57 +0.01 (+0.28%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$3.25▼$3.7850-Day Range$3.56▼$5.6752-Week Range$3.24▼$16.50Volume121,010 shsAverage Volume59,937 shsMarket Capitalization$32.63 millionP/E RatioN/ADividend YieldN/APrice Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Prenetics Global alerts: Email Address Prenetics Global MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,580.7% Upside$60.00 Price TargetShort InterestHealthy0.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.40) to ($0.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.44 out of 5 starsMedical Sector517th out of 939 stocksHolding & Other Investment Offices Industry6th out of 14 stocks 3.5 Analyst's Opinion Consensus RatingPrenetics Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.00, Prenetics Global has a forecasted upside of 1,580.7% from its current price of $3.57.Amount of Analyst CoveragePrenetics Global has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.10% of the float of Prenetics Global has been sold short.Short Interest Ratio / Days to CoverPrenetics Global has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Prenetics Global has recently decreased by 39.39%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrenetics Global does not currently pay a dividend.Dividend GrowthPrenetics Global does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRE. Previous Next 4.1 News and Social Media Coverage News SentimentPrenetics Global has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Prenetics Global this week, compared to 1 article on an average week.Search Interest7 people have searched for PRE on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows1 people have added Prenetics Global to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prenetics Global insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 25.01% of the stock of Prenetics Global is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Prenetics Global are expected to grow in the coming year, from ($1.40) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prenetics Global is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prenetics Global is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrenetics Global has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Prenetics Global Stock (NASDAQ:PRE)Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.Read More PRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRE Stock News HeadlinesFebruary 9, 2024 | finance.yahoo.comPrenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space StationFebruary 9, 2024 | globenewswire.comPrenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space StationMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… January 17, 2024 | msn.comPrenetics Global files to sell 1.48M Class A shares for holdersDecember 18, 2023 | investing.comPrenetics Global (PRE) Earnings Dates & ReportsDecember 17, 2023 | seekingalpha.comPRENW Prenetics Global Limited WT EXP 051827November 20, 2023 | benzinga.comPrenetics Global Stock (NASDAQ:PRE) Insider TradesNovember 20, 2023 | msn.comPrenetics Global GAAP EPS of -$0.08, revenue of $4.86MMarch 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.November 20, 2023 | benzinga.comPrenetics Global: Q3 Earnings InsightsNovember 20, 2023 | finance.yahoo.comPrenetics Announces Third Quarter 2023 Financial ResultsNovember 11, 2023 | finance.yahoo.comPrenetics Global Limited (NASDAQ:PRE): Is Breakeven Near?November 5, 2023 | morningstar.comPrenetics Global Ltd Class A PRENovember 1, 2023 | msn.comPrenetics Global announces reverse stock splitNovember 1, 2023 | finance.yahoo.comPrenetics Global Limited Announces Reverse Stock SplitOctober 30, 2023 | money.usnews.comPrenetics Global Limited - Ordinary Shares - Class AOctober 3, 2023 | finance.yahoo.comGenetic Genealogy Market | Direct-To-Customer Segment Registered The Highest Growth - Here's WhySeptember 15, 2023 | finanznachrichten.dePrenetics Global Limited: Prenetics Announces Second Quarter 2023 Financial ResultsSeptember 15, 2023 | finance.yahoo.comPrenetics Announces Second Quarter 2023 Financial ResultsSeptember 10, 2023 | finance.yahoo.comPRE - Prenetics Global LimitedAugust 29, 2023 | finance.yahoo.comA World's First: The Miss Hong Kong Pageant 2023 Unveiled Contestants' CircleDNA Results Live on TelevisionJuly 22, 2023 | fool.comPrenetics Global (NASDAQ: PRE)July 16, 2023 | finance.yahoo.comPrenetics Global (NASDAQ:PRE) investors are sitting on a loss of 78% if they invested a year agoJuly 4, 2023 | msn.comEx-Fave boss Joel Neoh takes on yet another role, co-creates a founder-led early-stage VCJune 30, 2023 | finance.yahoo.comPrenetics Global signs "transformational" $200mln deal to create cancer screening JVJune 29, 2023 | proactiveinvestors.comPrenetics Global signs "transformational" $200mln deal to...Prenetics Global signs "transformational" $200mln deal to create...June 26, 2023 | msn.comPrenetics Global Limited (PRE) Is Considered a Good Investment by Brokers: Is That True?See More Headlines Receive PRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prenetics Global and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/15/2023Today3/27/2024Next Earnings (Estimated)4/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:PRE CUSIPN/A CIK1876431 Webwww.prenetics.com Phone852-2210-9588FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+1,580.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.0786) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,450,000.00 Net Margins-55.31% Pretax Margin-29.55% Return on Equity-3.89% Return on Assets-3.10% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.53 Sales & Book Value Annual Sales$275.76 million Price / Sales0.12 Cash FlowN/A Price / Cash FlowN/A Book Value$26.27 per share Price / Book0.14Miscellaneous Outstanding Shares9,140,000Free FloatN/AMarket Cap$32.63 million OptionableNot Optionable Beta-0.08 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Sheng Wu Yeung (Age 45)Co-Founder & CEO Dr. Chi Hung Tzang Ph.D. (Age 49)Co-Founder, Chief Scientific Officer & Member of Scientific Advisory Board Mr. Hoi Chun Lo (Age 39)Chief Financial Officer Dr. Yung Ho Wong DPHIL (Age 42)Chief Technology Officer Ms. Yvonne L. WongChief Corporate Development OfficerMs. Samantha KwokVice President People & CultureDr. Senthil Sundaram M.D. (Age 50)Chief Clinical Officer Mr. Avrom Boris Lasarow (Age 47)Chief Executive Officer of EMEA Dr. Shih-Chang Ong M.D. (Age 46)Chief Medical Officer & Member of Scientific Advisory Board Mr. Joel NeohChief Consumer Officer & MD for CircleDNAMore ExecutivesKey CompetitorsCERo TherapeuticsNASDAQ:CEROPsyence BiomedicalNASDAQ:PBMFuture Health ESGNASDAQ:FHLTMiNK TherapeuticsNASDAQ:INKTFemasysNASDAQ:FEMYView All CompetitorsInstitutional OwnershipNomura Holdings Inc.Bought 113,288 shares on 3/27/2024Ownership: 2.122%Prudential PLCSold 9,591,997 shares on 2/14/2024Ownership: 7.493%Aspex Management HK LtdSold 4,846,100 shares on 2/14/2024Ownership: 3.787%Nomura Holdings Inc.Bought 113,288 shares on 2/14/2024Ownership: 2.122%View All Institutional Transactions PRE Stock Analysis - Frequently Asked Questions Should I buy or sell Prenetics Global stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prenetics Global in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRE shares. View PRE analyst ratings or view top-rated stocks. What is Prenetics Global's stock price target for 2024? 1 analysts have issued twelve-month price targets for Prenetics Global's shares. Their PRE share price targets range from $60.00 to $60.00. On average, they anticipate the company's stock price to reach $60.00 in the next year. This suggests a possible upside of 1,580.7% from the stock's current price. View analysts price targets for PRE or view top-rated stocks among Wall Street analysts. How have PRE shares performed in 2024? Prenetics Global's stock was trading at $5.91 at the start of the year. Since then, PRE shares have decreased by 39.6% and is now trading at $3.57. View the best growth stocks for 2024 here. Are investors shorting Prenetics Global? Prenetics Global saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 8,000 shares, a drop of 39.4% from the February 29th total of 13,200 shares. Based on an average trading volume of 56,300 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the shares of the stock are sold short. View Prenetics Global's Short Interest. When is Prenetics Global's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024. View our PRE earnings forecast. How were Prenetics Global's earnings last quarter? Prenetics Global Limited (NASDAQ:PRE) posted its quarterly earnings data on Friday, September, 15th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.15. The company earned $5.70 million during the quarter. Prenetics Global had a negative trailing twelve-month return on equity of 3.89% and a negative net margin of 55.31%. When did Prenetics Global's stock split? Prenetics Global shares reverse split before market open on Tuesday, November 14th 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Prenetics Global's major shareholders? Prenetics Global's stock is owned by many different retail and institutional investors. Top institutional shareholders include Prudential PLC (7.49%), Aspex Management HK Ltd (3.79%), Nomura Holdings Inc. (2.12%) and Nomura Holdings Inc. (2.12%). How do I buy shares of Prenetics Global? Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prenetics Global Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.